Skip to content

The treatment value of PPI in patients with OSAHS and GERD

The treatment value of PPI in patients with OSAHS and GERD

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOR-15007459
Enrollment
Unknown
Registered
2015-11-18
Start date
2015-12-31
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Sleep Apnea and Hyponea Syndrom, Gastroesophageal Reflux Disease

Interventions

CPAP therapy group:CPAP therapy
CPA+PPI therapy group:CPAP+PPI therapy

Sponsors

The First Affiliated Hospital, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. The subjects had to voluntarily participate and comply with the requirements of the study, understand and comply with the follow-up plan, correctly record rating scale, drug use frequency, along with drugs and adverse events, and sign a consent form; 2. Recruited patients aged between 18 to 70 years; 3. Sex unlimited but limited to Chinese. (4)Included patients should meet the index of AHI>15 and have Pathological GERD. (5)BMI between 24-28 including 24 and 28. (6)Not used acid-inhibitory drugs in 2 weeks.

Exclusion criteria

Exclusion criteria: 1. Patients with history of Tumor diseases, immunodeficiency, organ transplantation, coronary heart disease, myocardial infarction, severe emphysema and COPD, long-term use of insomnia, psychotropic drug,severe osteoporosis, Parkinson, respiratory tract infection in 2 weeks; 2. Patients are currently participating in other clinical studies or had attended other clinical studies in 30 days and researches of this study; 3. Patients with mental disorder,poor motives and abnormal intelligence which may affect the effectiveness of this study; 4. pregnant or lactating women; 5. Patients who are allergic to esomeprazole.

Design outcomes

Primary

MeasureTime frame
ESS;

Secondary

MeasureTime frame
SF-36 questionnaire;AHI;ACT;GERD symptoms scale;RSI scores;

Countries

China

Contacts

Public ContactLi Jian
13902236371@163.com+86 13902236371

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026